🔎 Trials Near Me

Почетна › Рак на бели дробови со не-мали клетки › Канзас

Клинички испитувања за Рак на бели дробови со не-мали клетки во Канзас

34 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во Канзас.

Градови во Канзас

Официјален текст на студијата (англиски)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • The University of Kansas Cancer Center - Olathe, Olathe
  • Cancer Center of Kansas - Pratt, Pratt
  • Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita
  • и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

  • Ascension Via Christi Hospitals Wichita, Wichita
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07293247

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • HaysMed, Hays
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06498635

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

  • Kansas City Cancer Center /ID# 273679, Overland Park
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • The University of Kansas Cancer Center, Westwood
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT06881784

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  • University of Kansas Cancer Center, Westwood
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT05498428

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  • Research Site, Westwood
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06218914

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Saint Luke's South Hospital, Overland Park
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University of Kansas Cancer Center, Fairway
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06667076

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  • Research Site, Leawood
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06868277

Pan-tumor MRD Study

  • Cotton O'Neil Cancer Center [Stormont Vail], Topeka
  • Cancer Center of Kansas, Wichita
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • Mercy Hospital Pittsburg, Pittsburg
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  • Cancer Center of Kansas, Wichita
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT06561386

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

  • University of Kansas, Westwood
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07020117

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Local Institution - 007-942-B, Chanute
  • Local Institution - 007-942-D, El Dorado
  • Local Institution - 007-942-E, Independence
  • и уште 12
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT04613596

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • University of Kansas Medical Center /ID# 263196, Westwood
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06236438

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • The University of Kansas Cancer Center - Westwood, Westwood
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06119581

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • University of Kansas Medical Center, Kansas City
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06343402

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Cancer Center-Overland Park, Overland Park
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT06500481

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • The University of Kansas Cancer Center, Kansas City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 11.8.2026 · NCT05592626

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • University of Kansas Medical Center (KUMC), Westwood
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT05579366

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • The University of Kansas Cancer Center, Investigational Drug Services, Fairway
  • The University of Kansas Clinical Research Center, Fairway
  • The University of Kansas Hospital, Kansas City
  • и уште 6
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 6.7.2026 · NCT04389632

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  • University of Kansas Cancer Center, Westwood
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.6.2026 · NCT06216301

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

  • The University of Kansas Cancer Center, Westwood
Се регрутираФаза 1/2
Возраст од 18 до 70 · Сите полови · Ажурирано 11.6.2026 · NCT05361174

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • и уште 7
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 3.6.2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • и уште 7
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 6.5.2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • и уште 7
Се регрутираФаза 2
18 Minutes · Сите полови · Ажурирано 5.5.2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • и уште 8
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 5.5.2026 · NCT06616584

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

  • The University of Kansas Cancer Center, Fairway
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 18.3.2026 · NCT06244771

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • HaysMed, Hays
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • и уште 6
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 17.3.2026 · NCT06418204

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

  • The University of Kansas Cancer Center (KUCC), Fairway
  • The University of Kansas Cancer Center, Westwood Campus, Kansas City
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.1.2026 · NCT04467723

A Study of IBI363 in Subjects with Advanced Solid Malignancies

  • University of Kansas Medical Center (KUMC), Fairway
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 19.12.2024 · NCT06281678

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

  • The University of Kansas Cancer Center, Westwood Campus, Kansas City
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 8.5.2024 · NCT04680377

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

  • The University of Kansas Cancer Center (KUCC), Fairway
  • The University of Kansas Cancer Center, Westwood Campus, Kansas City
Се регрутираНабљудувачка студија
Возраст од 18 до 110 · Сите полови · Ажурирано 23.2.2024 · NCT05332925

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.